[Department of Error] Department of Error
Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2017; 391: 230–40—In figure 2F of this Article (published online first on Nov 9, 2017), the confidence interval around the hazard ratio should have been 0·14–0·58. This correction has been made to the online version as of Nov 30, 2017, and the printed Article is correct.